MARTIN SHKRELI - 160 - 180Martin Shkreli IQ is estimated from 160 to 180. Hedge-fund manager Rex Dwyer, who invests in small companies, including some biotech firms, remembers being introduced to Shkreli at a conference. “He’s quirky,” Dwyer says. “He has a super-high I.Q. It must be 160 or 180. His brain just crunches on things and comes up with answers. I’d ask him a question and he’d stare at me and not say anything. It weirded me out, but I realized he’d just disappeared into his brain.”
After four years, Shkreli left, and bounced around a few other firms before starting his own, Elea Capital Management. In the summer of 2007, the fund tanked when Shkreli made a $2.6 million bet, through Lehman Brothers, that the market would decline. When he was wrong, he refused to pay Lehman, instead making “veiled threats of filing a bankruptcy,” according to a lawsuit. But it was Lehman which went down in flames, during the 2008 meltdown, and although the court found in its favor, the verdict was vacated.
“I wasn’t successful with my first hedge fund,” Shkreli says today. “I shut it down and lived with my parents. It was a fall from, well, not grace, but a fall.”
Around 2008, Shkreli started a second hedge fund, MSMB, a name made from his initials and those of his business partner and childhood friend, Marek Biestek. They developed a reputation for shorting biotech companies and then using stock chat rooms and other aggressive tactics to savage them, to cause the stock to go down. As Shkreli wrote for one investment site, “Clinical data can be misleading, innocently biased, meaningless, manipulated and sometimes even downright doctored.”
Martin Shkreli IQ must be very high. An investor points out, “Shkreli had a really good knowledge of who was faking drug results and who was gaming the system.” But, recalls another investor, he was “willing to take a lot of risk and do things other people won’t do.”
Some information about Martin ShkreliMartin Shkreli is an American business, former hedge fund manager, and convicted, currently incarcerated felon. With Martin Shkreli IQ, he is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, co-founder and former chief executive officer (CEO) of the biotechnology firm Retrophin, and founder and former CEO of Turing Pharmaceuticals. Shkreli is also the CEO of start-up software company Godel Systems, which he founded in August 2016.
In September 2015, Shkreli received widespread criticism when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price by a factor of 56 (from US$13.5 to US$750 per pill), leading him to be referred to as "the most hated man in America" and "Pharma Bro".
In December 2015, Shkreli was arrested by the FBI after being indicted on federal charges of securities fraud. He subsequently resigned as CEO of Turing Pharmaceuticals and was replaced by the company's board chairman, Ron Tilles. Shkreli was convicted of two counts of securities fraud and one count of conspiring to commit securities fraud in August 2017.